Lantern Pharma Inc. (LTRN) research
Lantern Pharma Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.86
- As of
Lantern Pharma Inc. (LTRN): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-01.
As of . Source: SEC EDGAR filings for LTRN. Method and limitations.
Share the LTRN intelligence card
See the full LTRN dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for LTRN on one page. Preview it with sample data, then open it live with a free account.
Preview the LTRN dossierActive signals for LTRN
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 27.8%, EPS $-0.28 vs $-0.3876 estimate
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +151% to LTRN (2026Q2)
- mediumEARNINGS_BEAT
Q2-2025: Beat consensus by 19.1% - EPS $-0.4 vs $-0.4947 estimate
- mediumEARNINGS_BEAT
Q3-2025: Beat consensus by 18.6% - EPS $-0.39 vs $-0.4794 estimate
- mediumEARNINGS_BEAT
Q4-2025: Beat consensus by 23.3% - EPS $-0.36 vs $-0.4692 estimate
FREE, NO ACCOUNT
Every signal on LTRN, as it fires
You are seeing 5 of 6 signals recorded on LTRN since 2026-05-17.
The five above landed across 3 days. The other 1 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in LTRN (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 51654W101 · 2026Q2 | $1.2M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 51654W101 · 2026Q2 | $200K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, LTRN
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
LTRN against its peers
LTRN's return on equity of -262.0% ranks in the 29th percentile of 18 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-06-30.
| Metric | LTRN | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 319857 | n/a | 12 |
| Operating margin | n/a | -3604.2% | n/a | 10 |
| Net margin | n/a | -3359.7% | n/a | 10 |
| Return on equity | -262.0% | -115.5% | 29 | 18 |
Peers (22): SYBX, TPST, CKDXF, HIND, ANEB, VTGN, DARE, BIVI, AEON, ICU, PASG, ALLR, CYCN, BCDA, GTBP, INAB, KTTA, CMMB, LSTA, PLUR, ASBP, INTS. Left out: ZIVO (period gap), HOOK (period gap), CTXR (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (LTRN: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more LTRN signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to LTRNand get the insider, 13F, options, and confluence read in one view.